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Abstract 
 
Reactive oxygen species (ROS) have been widely implicated in the pathogenesis of 
diabetes and more recently in mitochondrial alterations in skeletal muscle of diabetic mice. 
However, the exact sources of ROS in skeletal muscle remained so far elusive. Aiming at 
better understanding the causes of mitochondrial alterations in diabetic muscle, we designed 
this study to characterize the sites of ROS production in skeletal muscle of 
streptozotocin(STZ)-induced diabetic mice. Hyperglycaemic STZ mice showed increased 
markers of systemic and muscular oxidative stress, as evidenced by increased circulating 
H2O2 and muscle carbonylated protein levels. Interestingly, insulin treatment reduced 
hyperglycaemia and improved systemic and muscular oxidative stress in STZ mice. We 
demonstrated that increased oxidative stress in muscle of STZ mice is associated with an 
increase of xanthine oxidase (XO) expression and activity and is mediated by an induction of 
H2O2 production by both mitochondria and XO. Lastly, treatment of STZ mice, as well as 
high fat and high sucrose diet-fed mice, with oxypurinol reduced markers of systemic and 
muscular oxidative stress and prevented structural and functional mitochondrial alterations, 
confirming the in vivo relevance of XO in ROS production in diabetic mice. These data 
indicate that mitochondria and XO are the major sources of hyperglycaemia-induced ROS 
production in skeletal muscle and that the inhibition of XO reduces oxidative stress and 
improves mitochondrial alterations in diabetic muscle. 
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Introduction 
 
Altered lipid metabolism and mitochondrial dysfunction in skeletal muscle have been 
associated with insulin resistance and type 2 diabetes (13, 28). These alterations in 
mitochondria structure, density and/or function (23, 34, 36) have lead to the speculation that a 
decrease in the capacity to oxidize fat, due to acquired or inherited mitochondrial defect, may 
be the underlying cause of lipid accumulation and thus, as a consequence, of insulin resistance 
(24). However, we (5) and others (14, 37, 42, 45) have challenged this hypothesis, and we 
recently demonstrated that mitochondrial alterations are not a causal event in the development 
of diet-induced insulin resistance, but rather a consequence of oxidative stress in skeletal 
muscle of diabetic mice (5). Consequently, a better understanding of the exact sites of reactive 
oxygen species (ROS) generation in skeletal muscle is important in order to improve 
mitochondria alterations and reduce lipotoxicity. 
Oxidative stress has also been implicated in the pathogenesis of insulin resistance and 
diabetes, based in part on the role of ROS in micro- and macrovascular complications 
associated with hyperglycaemia in late-stage diabetes (38). Interestingly, ROS production is 
not confined to vascular cells and several data also suggest that ROS may be produced in 
many tissues, and particularly in insulin-sensitive tissues (12, 41). Among them, skeletal 
muscle is now recognized as a potential source of both ROS and reactive nitrogen species 
(RNS) under various physiological and pathological conditions (16). Type 1 and type 2 
diabetes-associated hyperglycaemia are pathological situations in which increased oxidative 
stress could affect the function of skeletal muscle (29). Furthermore, we have previously 
shown that acute hyperglycaemia induces a rapid down-regulation of a number of genes in 
skeletal muscle of healthy subjects, likely via a mechanism involving oxidative stress (32). 
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However, mechanisms responsible for the glucose-induced oxidative stress in skeletal muscle 
remain to be elucidated.  
 Several cellular sources could be involved in the production of ROS into muscle, 
including complexes I and III of the electron transport chain of mitochondria (3, 27), 
membrane-associated NADPH oxidase (10, 18), and xanthine oxydase (XO) (1). In addition, 
nitric oxide (NO) can also be generated by skeletal muscle, since both neuronal (type I) and 
endothelial (type III) isoforms of NO synthase (NOS) are expressed in this tissue (2). It has 
been demonstrated that NO is able to react with superoxides to generate peroxynitrite, 
suggesting possible interactions between ROS and RNS formed in skeletal muscle, leading to 
their reduced bioavailability and potentially altered cellular responses (4). In parallel, skeletal 
muscle possesses a well-developed system to regulate ROS and prevent potentially 
deleterious effects. These protection systems include both mitochondrial and cytosolic 
isoforms of superoxide dismutase (MnSOD and CuZnSOD, respectively), catalase and 
gluthatione peroxidase enzymes, and a number of direct scavengers of ROS. However, the 
relative importance of the production and protective pathways has not been established in 
skeletal muscle in diabetic states. Elucidation of this issue could help to prevent oxidative 
stress and associated muscle damages in this disease.  
 The goal of our study was thus to investigate the pathways involved in hyperglycemia-
induced ROS generation in skeletal muscle of diabetic mice. We have chosen to study the  
streptozotocin (STZ)-induced diabetic mice because we have previously demonstrated that 
oxidative stress induced similar mitochondrial alterations in both type 1 and type 2 diabetic 
mice (5). The identification of hyperglycaemia-induced ROS production systems in skeletal 
muscle of diabetic STZ mice was performed 1) by measuring the expression and/or enzyme 
activity of genes related to ROS production and protection and their regulation by insulin and 
antioxidant treatments in skeletal muscle, and 2) by measuring directly H2O2 production on 
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both isolated mitochondria and total muscle lysates. All together, our findings indicate that 
activation of mostly mitochondria and XO account for hyperglycaemia-induced production of 
ROS in diabetic muscle, and demonstrate for the first time a beneficial effect of oxypurinol, a 
XO inhibitor, on mitochondria alterations in skeletal muscle of both type 1 and type 2 diabetic 
mice. 
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Materials and Methods 
 
Animals: Animals were purchased from Harlan (Gannat, France) and housed in a room under 
controlled temperature and humidity and had free access to water and chow. All animal 
experiments were conducted in accordance with institutional guidelines for the care and use of 
laboratory animals, and regional ethic committee has approved protocols.  
Experiment 1: Ten week-old male C57Bl/6 mice (n=32) were given daily (at 9 hour a.m.) an 
ip dose of streptozotocin dissolved in sodium citrate buffer (STZ, 100 mg/kg body weight, 
Sigma), for 3 consecutive days. The control group (Co, n=16) was injected with sodium 
citrate buffer. Glucose levels were monitored daily and when STZ mice achieved fed glucose 
levels >500 mg/dl for 3 consecutive days (day 11), they were separated into two groups 
(n=16/group). One group was injected with saline solution and the second was treated with 
insulin (Insulatard®, 3mU), twice daily at 8-hour intervals. Twenty-four hours after the first 
injection of insulin, all animals were sacrificed and blood was collected and gastrocnemius 
muscles were removed and frozen in liquid nitrogen.  
Experiment 2: Another group of Co (n=10) and STZ mice (n=30) were made as described 
above. At day 8, STZ mice were separated in three groups (n=10/group). One group was 
untreated, the second one was treated with the general antioxidant N-acetyl-cysteine (NAC, 
10 g/l in the drinking water) and the third group was treated with oxypurinol (OXY, an 
inhibitor of xanthine oxidase, 1mM in the drinking water) until day 12. The concentration of 
oxypurinol was previously shown to inhibit XO (35). Fresh solutions were made each 48 
hours. At day 12, all mice were sacrificed and blood was collected and gastrocnemius muscles 
were removed and frozen in liquid nitrogen.  
Experiment 3: Male C57BL/6 mice at 4 weeks were fed with a standard diet (SD, 57% 
carbohydrate, 5% fat, 18% protein, Harlan) or with a pelleted high-fat and high-sucrose diet 
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(HFHSD) (36% fat, 35% carbohydrate (50% sucrose), and 19.8% protein; TD99249, Harlan) 
during 16 consecutive weeks. One group of HFHSD mice was treated with oxypurinol (1mM 
in the drinking water) during all the feeding period. During the last week of protocol, ip 
glucose and insulin tolerance tests (IPGTT and IPITT, respectively) were performed on 8h-
fasted mice. Mice were injected ip with 2 mg/g body weight of glucose or 0.75mU/g body 
weight of insulin. Blood was taken by tail puncture immediately before and different times 
after injection for measurements of plasma glucose. At the end of the protocol, mice were 
sacrificed, blood was collected at the fed state and gastrocnemius muscles were fixed for 
electronic microscopy analysis. 
 
Measurement of metabolites and hormones: Blood glucose levels were measured using a 
glucometer (Roche Diagnostics, Meylan, France). Serum levels of insulin were determined 
using the murine ELISA kits (Linco Research, Missouri, USA). Plasma H2O2 levels were 
measured using an Amplex Red hydrogen peroxide assay kit (Invitrogen, Cergy Pontoise, 
France). Specificity of the signal for H2O2 was confirmed by treating plasma with 
polyethylene glycol catalase (100U/ml). 
 
Real time quantitative RT-PCR analysis: Total RNA was extracted with the Trizol Reagent 
(Invitrogen, Cergy Pontoise, France). The level of target mRNAs were measured by RT 
followed by real-time PCR, using a LightCycler (Roche Diagnostics, Meylan, France). Primer 
sequences are listed in Table S1. We measured hypoxanthine guanine phosphoribosyl 
transferase (HPRT) mRNA as a reference gene, so that the results are expressed as a ratio 
referred to the expression of HPRT.  
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Protein carbonylation: The Oxyblot Oxidized Protein Detection Kit was purchased from 
Chemicon (Hampshire, UK). The carbonyl groups in the protein side chains are derivatized to 
DNP-hydrazone by reaction with DNPH, following the manufacturer’s instructions. After the 
derivatization of the protein sample (20µg), one dimensional electrophoresis was carried out 
on a 10% SDS-PAGE gel. Proteins were transferred to PVDF-membranes. After incubation 
with anti-DNP antibody, the blot was developed using a chemiluminescence’s detection 
system. After transfers, the gels were stained with coomassie blue to verify protein loading. 
These gels were scanned and the intensity of each line allowed the normalization of the 
densitometry analysis of carbonylated proteins. 
 
Measurement of enzymes activities: Xantine oxidase activity was measured using the 
Amplex Red Xantine Oxidase assay kit from Molecular Probes (Molecular Probes, 
MP22182), according to the instructions of manufacturer. NOS activity was measured using 
the Ultrasensitive colorimetric assay for Nitric Oxide Synthase from Euromedex (Euromedex, 
NB78), according to the instructions of manufacturer. NAD(P)H oxidase activity was 
measured according to the protocol of Iverson et al (Iverson D, et al., JCI 1977). Briefly, 
200µg of skeletal muscle proteins were incubated 60 min at 37°C in a 100µL volume 
containing 0.1M potassium phosphate buffer pH5.5, 2mM KCN and 200µM NAD(P)H. The 
incubation was stopped by the addition of 0.4N HClO4 and proteins were removed by 
centrifugation. 40µL of the resulting supernatant was added to 60µL of NaOH 10N and 
allowed to incubate for 1h at room temperature. 100µL of water was added to each sample 
and fluorescence was measured in a fluorimeter equipped with a 355 nm primary filter and a 
460 nm secondary filter. 
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Muscle lysates and isolation of muscle mitochondria: Gastrocnemius and quadriceps 
muscles were quickly removed and placed in ice-cold lysis medium (100mM sucrose, 50 mM 
KCl, 5 mM EGTA, and 50 mM Tris/HCl, ph 7.4). Muscles were cleaned of extracellular fat 
and connective tissue, minced with scissors and used either for muscle lysates (right limb) or 
for isolation of mitochondria (left limb). For lysates, muscle was homogenized in 1.5 ml of 
lysis medium and centrifuged at 800 g for 10 minutes. For isolation of mitochondria, muscle 
was cut in small pieces in isolation buffer (Mannitol 210mM, Saccharose 70mM, Tris 50mM, 
EDTA 10mM and BSA 0.5%, pH=7.4). Then, it was digested 15 minutes with trypsin, under 
agitation, and washed 2 times with the isolation buffer. After each wash, the tissue was 
centrifuged two minutes, at 70g. The tissue was homogenized with a conical glass grinder 
(VWR International) in isolation buffer. The homogenate was centrifuged 10 minutes at 820g. 
Then the supernatant was centrifuged 20 minutes at 6800g. The pellet was resuspended in 
suspension buffer (Mannitol 225mM, Saccharose 75mM, Tris 10mM, and EDTA 0.1mM, 
pH=7.4) and centrifuged 10 minutes at 820g. The mitochondria were then pelleted by 
centrifuging the supernatant 20min at 6800g, and resuspended in 100µl of the same buffer. 
Protein quantification of muscle lysates and isolated mitochondria was measured by the 
Biuret method with BSA as standard. 
 
Mitochondrial H2O2 production: Generation of mitochondrial H2O2 was determined on an 
SFM25 computer-controlled Kontron fluorometer by measuring the linear increase in 
fluorescence (excitation at 560 nm, emission at 584 nm) due to enzymatic oxidation of 
amplex Red by H2O2 in the presence of horseradish peroxidase. Mitochondria (0.1 mg/ml) 
were incubated at 30 °C in a buffer containing 125 mM KCl, 20 mM Tris-HCl, 1 mM EGTA, 
0.15% fat free BSA (pH 7.2) and containing 6 U/ml of horseradish peroxidase and 1 µM 
Amplex Red. The reaction was started by addition of succinate (5 mM). Mitochondrial H2O2 
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was measured in basal conditions, and 2 M rotenone and 2 M antimycin A were sequentially 
added to determine the maximum rate of H2O2 production of complexes I and I+III of the 
respiratory chain, respectively. To verify the specificity of the Amplex Red reaction with 
H2O2, catalase (100U/ml) was also added to mitochondria. 
 
Xanthine oxidase-mediated H2O2 production: Generation of H2O2 by the xanthine oxidase 
was determined in the same conditions as in mitochondrial H2O2 production. Muscle Lysates 
(100 µl) were incubated at 30 °C in a buffer containing 125 mM KCl, 20 mM Tris-HCl, 
1 mM EGTA, 0.15% fat free BSA (pH 7.2) and containing 6 U/ml of horseradish peroxidase 
and 1 µM Amplex Red. The H2O2 production was measured in the basal state and the reaction 
was started by the addition of xanthine (1.5 µM). Lastly, Allopurinol (100 µM), a XO 
inhibitor, was added to demonstrate the implication of xanthine oxidase in the measured H2O2 
production. 
 
Measurement of ATP synthesis: ATP synthesis by isolated mitochondria from skeletal 
muscle was measured according to the protocol of Vives-Bauza C et al (44). Briefly, freshly 
isolated mitochondria were diluted in 160µL of a specific buffer (150 mM Kcl, 25 mM Tris-
Hcl, 2 mM EDTA, 0,1% BSA, 10 mM potassium phosphate, pH 7,4) containing P1,P5-
di(adenosine) pentaphosphate (0.15 mM). Luciferin, Luciferase, ADP, and either malate plus 
pyruvate (to 1mM) or succinate (to 5 mM) plus 2µg/mL rotenone were added to the 
mitochondria suspension. Measurements of ATP synthesis were performed using a 
luminometer, which allow recordings in the kinetic mode. To obtain baseline fluorescence 
corresponding to nonmitochondrial ATP production, one replicate tube for each sample was 
prepared containing the components described above plus 1µg/mL oligomycin. 
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Transmission electron microscopy: Transmission electron microscopy on skeletal muscle 
was performed as previously described (5). Briefly, gastrocnemius muscle was cut into small 
pieces and fixed in 2% glutaraldehyde for 2h at 4°C, postfixed in 1% Osmium tetroxide for 1h 
at 4°C, dehydrated and embedded in Epon at eitheir a longitudinal or transverse orientation. 
The tissue was then cut using a RMC/MTX ultramicrotome (Elexience) and ultrathin sections 
(60-80nm) were mounted on copper grids, contrasted with 8% uranyl acetate and lead citrate, 
and observed with a Jeol 1200 EX transmission electron microscope (Jeol LTD) equipped 
with MegaView II high resolution TEM camera. Analysis was performed with Soft Imaging 
System (Eloïse SARL).  
 
Statistical analysis: Two-way ANOVA was used to analyze the differences between 
experimental groups. P<0.05 was considered to be significant.  
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Results 
 
Increased oxidative stress in skeletal muscle of STZ mice.  
To determine whether oxidative stress takes place in skeletal muscle in diabetic state, 
we analyzed STZ-induced diabetic mice, as a model of hyperglycaemia-associated oxidative 
stress without obesity. In addition, we examined the effect of acute insulin treatment (in order 
to reduce hyperglycaemia) on systemic and muscle oxidative stress in STZ mice. As shown in 
Table 1, STZ mice exhibited decreased body weight (20%, p<0.001), severe hyperglycaemia 
(225%, p<0.001), hypoinsulinemia (77.5%, p<0.001) and increased plasma H2O2 levels 
(121%, p<0.001), demonstrating type 1 diabetes-associated systemic oxidative stress. The 
specificity of H2O2 measurement in plasma was validating using catalase, which inhibits the 
amplex red signal (data not shown). Insulin treatment of STZ mice increased body weight 
(12%, p<0.01), decreased glucose levels (19%, p<0.001), and significantly reduced plasma 
H2O2 levels (-38%, p<0.05), compared to untreated STZ mice. 
As a marker of muscle oxidative stress, we measured total protein carbonylation levels 
in gastrocnemius muscle of control, untreated STZ mice, and insulin-treated STZ mice. As 
illustrated in Figure 1A, protein carbonylation is markedly increased in skeletal muscle of 
STZ mice compared to control mice, suggesting an oxidative stress in muscle of diabetic 
mice. Insulin treatment reduced protein carbonylation in skeletal muscle of STZ mice, 
compared to untreated STZ mice, suggesting a reduction of ROS production and/or an 
increase of antioxidant defences, in muscle of insulin-treated STZ mice. 
Next, we evaluated ROS activity and their production sites. We first measured changes 
in mRNA levels of oxidant and antioxidant enzymes, in skeletal muscle of mice. Concerning 
pro-oxidant enzymes, we measured the mRNA levels of 1) uncoupling proteins (UCP) 2 and 
3, as markers of mitochondria-mediated ROS production, 2) gp91, p22, p40, p47 and p67 
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subunits of NADPH oxidase, 3) xanthine oxidase (XO) and 4) the endothelial (NOS3) and 
neuronal (NOS1) NO synthase, as an index of RNS production. We found that UCP2, UCP3, 
and XO mRNA levels were significantly increased in skeletal muscle of STZ mice compared 
to control mice, whereas none of the subunit of NADPH oxidase, as well as NOS1 and NOS3 
were altered (Figure 1B), suggesting that ROS production in skeletal muscle of diabetic mice 
may mainly implicate mitochondria and XO. Insulin treatment restored the mRNA levels of 
UCP2 (p<0.05) and UCP3 (p=0.06), whereas expression of XO was not affected compared to 
untreated STZ mice. Concerning antioxidant enzymes, we investigated expression levels of 
enzymes implicated either in the reduction of superoxide (superoxide dismutase 2, SOD2) or 
in the detoxification of hydrogen peroxide (glutathione reductase (GSR), glutathione 
peroxidase (GPx), catalase, pioredoxine (Prdx) 3 and 5). STZ-induced diabetic mice exhibited 
increased mRNA levels of GSR and CAT, and reduced expression of SOD2 in skeletal 
muscle, whereas Prdx3, Prdx5, and GPx expression were not altered (Figure 1B). Insulin 
treatment restored catalase mRNA levels, whereas GSR expression was not affected, 
compared to untreated STZ mice (Figure 1B). In addition, insulin further reduced SOD2 
expression in skeletal muscle of STZ mice (Figure 1B). 
Then, we measured enzyme activities of pro-oxidant enzymes. As shown in Figure 
2A, XO activity was significantly increased in skeletal muscle of STZ mice compared to Co 
mice (35%, p<0.01), whereas neither NADPH oxidase nor NOS activities were modified. 
Insulin treatment did not modify any of these activities (Figure 2A). 
All together, these results indicate that there is an increase of oxidative stress markers 
in skeletal muscle of STZ-induced diabetic mice, which could be mediated either by an 
increase of mitochondria and XO-mediated ROS production and/or by a reduction of some 
antioxidant enzymes (SOD2).  
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Increased mitochondria and xanthine oxidase-mediated H2O2 production in STZ mice.  
To confirm the implication of mitochondria in hyperglycaemia-induced ROS 
production, we measured succinate-induced H2O2 production by isolated muscle mitochondria 
of control, untreated and insulin-treated STZ mice (n=6), in nonphosphorylated conditions 
(33). We have validated the specificity for H2O2 measurement by demonstrating that the 
addition of catalase inhibited the Amplex Red signal (data not shown). As shown in Figure 
2B, succinate (providing FADH2 to complex II of electron transfer chain) induced H2O2 
production by control mitochondria (+25 fold, p<0.01), and this production is drastically 
inhibited by rotenone (-84%, p<0.01), suggesting that it is mainly due to an enhanced ROS 
generation through a reverse electron flow at the level of complex I of the respiratory chain. 
Then, addition of antimycin A modestly induced H2O2 production, compared to that measured 
with rotenone (Figure 2B), indicating a weak implication of complex III in H2O2 production 
energized with succinate. Interestingly, the rate of H2O2 production by STZ mice derived 
mitochondria was significantly higher than from control mice (+164%, p<0.05, Figure 2B), 
indicating an increase of mitochondrial H2O2 production in skeletal muscle of STZ mice. 
Insulin treatment of the mice tended to reduce mitochondria H2O2 production energized with 
succinate (-65%, p=0.07, Figure 2B). 
To confirm the implication of XO in hyperglycaemia-induced ROS production, we 
accessed xanthine-stimulated H2O2 production on total muscle lysates of control, untreated 
and insulin-treated STZ mice (n=6). As shown in Figure 2C, xanthine induced H2O2 
production by control muscle lysates (1.6 fold, p<0.05), and this production is totally 
inhibited by addition of allopurinol (p<0.01), confirming the involvement of XO in the 
measured H2O2 production. Interestingly, the rate of xanthine-induced H2O2 production by 
STZ muscle lysates was significantly higher than in muscle lysates from control mice (+45%, 
p<0.05, Figure 2C), suggesting that XO participate to the increase of ROS production in 
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skeletal muscle of STZ mice. Once again, insulin treatment tended to reduce xanthine-induced 
H2O2 production compared to untreated STZ mice (-87%%, p=0.06, Figure 2C). 
Taken together, our results indicate that both complex I of mitochondria and XO 
contribute to increased H2O2 production in skeletal muscle of hyperglycaemic STZ mice.  
 
Inhibition of XO by oxypurinol treatment reduces oxidative stress in STZ mice 
We then sought to determine whether inhibition of XO could improve oxidative stress 
in skeletal muscle of diabetic mice in vivo. STZ mice were treated with oxypurinol (1mM) 
during 7 consecutives days and measured the consequences on systemic and muscle oxidative 
stress markers. In parallel, another group was treated with a general antioxidant, the N-
Acetylcysteine (10 g/l). The metabolic data of the animals were presented in Table 2. 
Oxypurinol treatment reduced circulating H2O2 (-36%, p<0.01), without change on plasma 
glucose and insulin levels, compared to untreated STZ mice (Table 2). NAC-treated STZ mice 
showed an improvement of glycaemia (21%, p<0.05), without significant change of 
circulating insulin and H2O2 levels, compared to untreated STZ mice (Table 2). Concerning 
muscle oxidative stress, treatment of STZ mice with oxypurinol reduced muscle protein 
carbonylation levels (-30%, p<0.05), compared to untreated STZ mice (Figure 3A). Similarly, 
NAC treatment decreased protein carbonylation levels compared to untreated STZ mice 
(Figure 4A). In addition, mRNA levels of almost all oxidant and antioxidant enzymes were 
poorly regulated by both antioxidants (Figure 3B and 4B). We only observed a decrease of 
mRNA levels of p22 and p40 subunits of NAD(P)H oxidase and of GSR, in oxypurinol-
treated STZ compared to untreated STZ mice (Figure 3B). All together, these results show 
that inhibition of XO by oxypurinol is sufficient to improve circulating and muscular 
oxidative stress markers in STZ-induced diabetic mice.  
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Treatment of STZ mice with oxypurinol improved mitochondria structure and function.  
We have previously demonstrated that oxidative stress in hyperglycaemic STZ mice is 
associated with altered mitochondria structure and function in skeletal muscle and that NAC 
treatment restored mitochondrial alterations (5). Since we demonstrated here that XO is 
implicated in hyperglycemia-associated muscle oxidative stress, we investigated whether 
oxypurinol treatment could also have a beneficial effect on mitochondria structure and 
density. First, we confirmed that oxypurinol specifically inhibited XO activity in skeletal 
muscle of STZ mice, whereas NADPH and NOS activities were not modified by oxypurinol 
treatment (Figure 5). Then, we analyzed by electronic microscopy the structure and density of 
mitochondria in muscle of Co, untreated STZ, and oxypurinol-treated STZ mice. As shown in 
Figure 6, we observed both a reduction of mitochondria density as well as important 
alterations of both subsarcolemmal and intermyofibrillar mitochondria structure in skeletal 
muscle of STZ mice compared to Co mice. These alterations included mitochondria swelling, 
an increased number of disarrayed cristae and a reduced electron density of the matrix. 
Interestingly, oxypurinol treatment improved these structural alterations, since we observed 
an increase of mitochondria number per section and a restoration of both cristae structure and 
electron density of the matrix (Figure 6), suggesting a role of XO in mitochondrial alterations 
in muscle of STZ mice.  
We then measured ATP production by isolated mitochondria in order to access 
mitochondria function in muscle of untreated and oxypurinol-treated STZ mice. As shown in 
Figure 7, ATP production mediated by succinate in presence of rotenone is reduced in muscle 
of STZ mice compared to Co mice (-30%, p<0.05), whereas ATP production mediated by 
complex I substrates (glutamate + malate) was not modified. Interestingly, oxypurinol 
treatment restored succinate-induced ATP production in muscle of STZ mice (Figure 7). 
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All together, these data indicate that reduction of XO activity improves mitochondria 
structure and function in muscle of STZ mice. 
 
Effect of oxypurinol treatment in diet-induced diabetic mice.  
To determine whether oxypurinol treatment could also be beneficial for mitochondrial 
alterations in a model of type 2 diabetes, we investigated mitochondria structure in standard 
diet fed mice (SD), high-fat and high-sucrose diet fed mice (HFHSD), and in oxypurinol-
treated HFHSD mice, during 16 weeks. Metabolic characteristics of these mice were shown in 
Table 3. HFHSD feeding induced clearly an obese and diabetic phenotype compared to SD 
mice, since HFHSD mice weighted 18 g more, were hyperglycaemic and hyperinsulinemic 
(Table 3) and showed altered response to glucose and insulin tolerance tests (Table 3).  In 
addition, circulating H2O2 levels are increased in HFHSD mice compared to SD mice (Table 
3). Treatment of HFHSD mice with oxypurinol did not modify body weight, glycaemia and 
insulinemia, and response to glucose and insulin tolerance tests. Nevertheless, oxypurinol 
treatment reduced plasma H2O2 levels in HFHSD mice, compared to untreated mice (Table 3). 
As previously described (5), HFHSD mice showed altered mitochondria structure compared 
to SD mice, as demonstrated by the reduction and the swelling of both subsarcolemmal and 
intermyofibrillar mitochondria, associated with the increased number of disarrayed cristae and 
the reduced electron density of the matrix (Figure 8). Interestingly, oxypurinol treatment 
improved these alterations in muscle of HFHSD mice (Figure 8), confirming the preventive 
effect of blocking XO-mediated ROS production on mitochondria structure in diet-induced 
diabetic mice. 
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Discussion 
 
 Hyperglycaemia-induced systemic oxidative stress is a classical feature of diabetes. In 
addition, we have recently demonstrated that oxidative stress is one of the culprits of 
mitochondrial dysfunction in skeletal muscle of both STZ and diet-induced diabetic mice (5). 
However, whether muscle ROS generation is really increased and the intrasubcellular sources 
of production in diabetic states are poorly known. The purpose of our study was to investigate 
this issue in STZ-induced diabetic mice, which share similar oxidative stress-induced 
mitochondrial alterations than diet-induced diabetic mice, in order to identify the main 
sources of hyperglycemias-induced ROS production in skeletal muscle. Then, specific 
antioxidant strategies were tested in both models in order to study the repercussions on 
mitochondria alterations in skeletal muscle of diabetic mice.  
 In the present study, we used STZ-induced diabetic mice as a classical model of 
hyperglycaemia-induced oxidative stress (39), and we treated these mice with insulin, NAC or 
oxypurinol in order to prevent this process.  STZ is used 
extensively to induce 
pancreatic beta cell death and 
ultimately diabetes mellitus in 
animal models. Whereas the direct 
effects of STZ on muscle can not be 
exclude (21), the comparison of phenotype between STZ and STZ+INS should help to 
delineate the effects of STZ from the effects of hypoinsulinemia/hyperglycaemia. STZ-
treated mice showed hyperglycaemia, hypoinsulinemia and increased systemic and muscular 
oxidative stress, compared to control mice. Interestingly, insulin treatment decreased both 
plasma glucose and H2O2 levels and markedly reduced intramuscular protein carbonylation, 
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suggesting that hyperglycaemia (and not STZ treatment per se) could be directly causal in 
muscle ROS production. Nevertheless, we cannot exclude that hypoinsulinemia also 
contributed to increased oxidative stress in STZ mice and that insulin treatment per se 
participated to reduced oxidative stress in muscle of insulin-treated STZ mice. Indeed, the 
reduction of hyperglycaemia by insulin treatment is modest in STZ mice, whereas insulin-
induced improvement of both circulating and muscle oxidative stress is more marked. We 
believe that the apparent mild reduction in glycaemia obtained after ip insulin administration 
in STZ mice reflected transitory action of insulin under our experimental procedure (two 
administrations of insulin, 24 h and 15 h before sacrifice). Despite the rebound of glycaemia 
after insulin infusion, muscle protein carbonylation and, more importantly, structure and 
density of mitochondria were restored (5). These results suggest that in addition to the 
improvement of glycaemia, specific effects of insulin should be taken into account to explain 
the reduction of oxidative stress and mitochondria rescue. These observations are in 
agreement with recent data demonstrating a beneficial effect of insulin on LPS-induced 
oxidative stress independent of any change in glucose concentrations (8). Whereas the 
molecular mechanisms by which insulin can reduce oxidative stress require further 
investigations, we can already conclude from our study that it does not involve a regulation of 
pro-oxidant enzymes activities, since they are not regulated by insulin treatment in muscle of 
STZ mice. 
 Two important points arising from our study are that skeletal muscle of diabetic mice 
showed increased ROS production and that this production is mediated by both the complex I 
of mitochondria and XO. This was supported by several independent experiments. Firstly, 
data on the expression of gene implicated in ROS production and protection, suggest that 
oxidative stress in STZ mice is more related to an increase of ROS production than a decrease 
of antioxidant defences. Indeed, the mRNA levels of antioxidant enzymes are weakly 
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deregulated in skeletal muscle of STZ mice, except for SOD2 that showed reduced 
expression. The others are either induced (GSR or catalase) or not regulated (Gpx, prdx3 and 
prdx5). On the opposite, mRNA levels of UCP2, UCP3 and XO were significantly increased 
in skeletal muscle of STZ mice, suggesting contribution of mitochondria and XO in ROS 
production. This was further supported by the increase of XO activity, without modification 
of both NADP and NOS activities, in skeletal muscle of STZ mice. The final proof was given 
by the direct measurements of H2O2 production in skeletal muscle of STZ mice. To our 
knowledge, there is sparse work directly measuring ROS production in diabetic skeletal 
muscle, and generally these measurements were performed on isolated mitochondria. Here, 
we measured H2O2 production by mitochondria, but also we tried to investigate XO-induced 
H2O2 production, by measuring xanthine-stimulated H2O2 production on total muscle lysates. 
The specificity of XO-related ROS production was confirmed by inhibition with allopurinol, 
an inhibitor of XO. We observed both an increase of H2O2 production by isolated 
mitochondria, and an increase of xanthine-induced H2O2 production in skeletal muscle of STZ 
mice compared to control mice, confirming the implication of both pathways in ROS 
production in skeletal muscle of diabetic mice. Consequently, the increase of both XO 
expression and activity participate to increased ROS production in skeletal muscle of STZ 
mice. 
It is not surprising that mitochondria was implicated in hyperglycaemia-induced ROS 
production, since mitochondria were known to be the major site of ROS production in many 
tissues and in a wide range of pathological conditions (19). Most importantly, our results 
showed that XO, a key enzyme of purine metabolism, is also a significant cellular source of 
ROS production in muscle of diabetic mice. Normally, XO activity is low in skeletal muscles 
(6). However, ROS production by XO is favoured by an accumulation of intracellular ADP 
(20). Consequently, mitochondrial dysfunction observed in skeletal muscle of STZ mice (5) 
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may lead to an imbalance of ATP/ADP ratio in the cytosol and an associated increase of XO 
activity. XO was reported to localize in capillary endothelial cells (17) and in the sarcolemma 
(15). Consequently, we cannot exclude that part of XO activity arises from endothelial cells. 
In addition, it was difficult to evaluate whether mitochondria and XO have additive effects on 
ROS production in vivo since the structure of mitochondria is altered in muscle of STZ. 
Indeed, we have observed by electron microscopy that purified mitochondria of both control 
and STZ mice were equally intact (data not shown), suggesting that the most damaged 
mitochondria were lost during differential centrifugation. Since it is not known whether the 
most damaged mitochondria can produce or not superoxide, it is not possible to conclude on 
the relative implication of both sources of ROS in vivo. It is likely that both are implicated but 
maybe with different kinetics during the development of STZ-induced diabetes. The 
implication of XO in ROS production by skeletal muscle of diabetic mice are supported by 
other studies demonstrating either that type 1 diabetes is associated with XO-mediated ROS 
production in other tissues (9, 30) or that skeletal muscle is able to generate ROS through XO 
in other physiopathological situations (22, 26, 43).  
To assess whether XO could be a potential target to protect against damages associated 
to oxidative stress in diabetes, we have treated STZ with oxypurinol and measured 
consequences on systemic and muscular oxidative stress markers. Oxypurinol treatment 
reduced both circulating H2O2 concentrations and muscle protein carbonylation levels, 
confirming the implication of XO in hyperglycaemia-induced ROS production in skeletal 
muscle of STZ mice. Interestingly, oxypurinol treatment restored structural and functional 
alterations of mitochondria in skeletal muscle of STZ mice, indicating that XO inhibition 
could be useful to prevent muscle damage. The expression of XO is not modified by 
oxypurinol treatment, indicating that the action of the drug only involved inhibition of XO 
activity. The inhibition of XO by oxypurinol probably led to a decrease in cytosolic ROS 
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production, contributing to the observed reduced protein oxidation. Nevertheless, we cannot 
exclude that the decrease of circulating H2O2 participated to the reduced protein carbonylation 
in skeletal muscle of STZ mice. This systemic effect of oxypurinol suggests that XO is also a 
major source of ROS in vascular cells, confirming previous data (31). Since ROS was 
implicated in hyperglycemia-induced diabetic complications (7), it is tempting to hypothesize 
that inhibition of XO could be benefit to improve micro- and macrovascular complications 
associated with diabetes. Interestingly, we confirmed the beneficial effect of oxypurinol 
treatment on mitochondrial alterations in skeletal muscle of diet-induced diabetic mice, a 
model of type 2 diabetes. This preventive effect was not accompanied by change neither in 
plasma glucose or insulin levels, nor in response to IPGGT and IPITT, suggesting that 
improvement of mitochondria integrity by oxypurinol is not sufficient to improve insulin 
sensitivity in HFHSD mice. Since diet-induced diabetic mice have a more complex metabolic 
phenotype, with an increase of both circulating and ectopic lipid levels and of inflammation, it 
is likely that other pro-oxidant enzymes (11) and/or other stress-activated pathways are 
always activated, and participate to the maintain of insulin resistance. Nevertheless, this result 
is an additional argument claiming that mitochondrial dysfunction is not a causal event of 
insulin resistance (14, 37, 42, 45). Nevertheless, by promoting intramuscular lipid 
accumulation, mitochondrial dysfunction could participate to the maintenance or to the 
exacerbation of impaired insulin sensitivity. Consequently, our data suggest that the inhibition 
of XO should be a useful strategy to improve mitochondrial alterations, in order to stimulate 
oxidative capacities and to reduce lipotoxicity. In agreement, XO activity is induced in type 2 
diabetic patients (25). Interestingly, allopurinol is classically used in clinic to treat gout, and 
patients who are affected by gout show increased circulating uric acid levels and a 
predisposition to metabolic syndrome (40). Nevertheless, further studies are needed to 
confirm whether the inhibition of XO may have benefits for diabetic patients. 
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In summary, the present study demonstrates that there is a hyperglycaemia-induced 
oxidative stress in skeletal muscle of diabetic mice, which results more from an increase of 
free radicals production rates than a reduction of endogenous antioxidants levels. In addition, 
our data provide in vivo evidences for the contribution of both mitochondria and XO to 
muscle oxidative stress in state of diabetes. The implication of XO is significant since 
oxypurinol treatment is able to reduce protein oxidation and improve mitochondrial 
alterations in both type 1 and type 2 models of diabetic mice. Consequently, XO might be a 
potential therapeutic target for decreasing muscle damages associated with oxidative stress, 
and more particularly, for improving oxidative capacities of muscle in diabetic states. 
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FIGURE LEGENDS 
 
Figure 1:Increased oxidative stress in skeletal muscle of STZ mice and improvement by 
insulin treatment. Control or STZ-induced diabetic mice were studied 12 days after the first 
injection of sodium citrate buffer or STZ, and insulin was injected to STZ mice, twice at 8 
hours of interval, during the last 24 hours of the protocol. A: A representative immunoblot 
showing total protein carbonylation in the gastrocnemius muscle of control (Co), 
streptozotocin-induced diabetic mice (STZ) and insulin-treated STZ mice (STZ+INS). At the 
right side, densitometry analysis of protein carbonylation, which are expressed relative to Co 
mice. Values are means ± sem (n=3). * p<0.05 vs. Co, $ p<0.05 vs. STZ. B: mRNA levels of 
oxidant and antioxidant enzymes, measured by real-time RT-PCR, in gastrocnemius muscle 
of Co, STZ and STZ+INS mice. Values are normalized to the levels of HPRT mRNA and 
expressed as relative amount compared to control mice. Data are expressed as means ± sem 
(n=6-10). * p<0.05 vs. Co. $ p<0.05 vs. STZ.  
 
Figure 2: Increased xanthine oxidase activity and increased H2O2 production mediated 
by mitochondria and xanthine oxidase in skeletal muscle of STZ mice. Control or STZ-
induced diabetic mice were studied 12 days after the first injection of sodium citrate buffer or 
STZ, and insulin was injected to STZ mice, twice at 8 hours of interval, during the last 24 
hours of the protocol. A: Xanthine oxidase (XO), NADPH oxidase and No synthase (NOS) 
activities measured in muscle lysates of control (Co), streptozotocin-induced diabetic mice 
(STZ) and insulin-treated STZ mice (STZ+INS). Values are the means ± sem (n=5). * p<0.01 
vs Co mice. B: Mitochondrial H2O2 release by skeletal muscle of Co, STZ and STZ+INS 
mice. Values are the means ± sem (n=6). * p<0.01 vs. basal H2O2 release. # p< 0.01 vs. 
succinate. $ p< 0.05 STZ mice vs. control mice. C: Xanthine oxidase-mediated H2O2 release 
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by skeletal muscle of Co, STZ and STZ+INS mice. Values are the means ± sem (n=6). * 
p<0.005 vs. basal H2O2 release. # p< 0.01 vs. Xanthine. $ p< 0.05 STZ mice vs. control mice. 
 
Figure 3: Treatment of STZ mice with oxypurinol improved oxidative stress in skeletal 
muscle. Control or STZ-induced diabetic mice were studied 12 days after the first injection of 
sodium citrate buffer or STZ, and oxypurinol was added to drinking water of STZ mice 
during the last 5 days of the protocol. A: A representative immunoblot showing total protein 
carbonylation in the gastrocnemius muscle of control (Co), Streptozotocin-induced diabetic 
mice (STZ) and oxypurinol-treated STZ mice (STZ+OXY). At the right side, densitometry 
analysis of protein carbonylation, which are expressed relative to Co mice. Values are means 
± sem (n=3). * p<0.05 vs. Co, $ p<0.05 vs. STZ.  B: mRNA levels of oxidant and antioxidant 
enzymes, measured by real-time RT-PCR, in gastrocnemius muscle of Co, STZ and 
STZ+OXY mice. Values are normalized to the levels of HPRT mRNA and expressed as 
relative amount compared to untreated STZ mice. Data are expressed as mean ± sem (n=6-
10). * p<0.05, ** p<0.01. 
 
Figure 4: Treatment of STZ mice with NAC improved oxidative stress in skeletal 
muscle. Control or STZ-induced diabetic mice were studied 12 days after the first injection of 
sodium citrate buffer or STZ, and N-acetylcystein was added to drinking water of STZ mice 
during the last 5 days of the protocol. A: A representative immunoblot showing total protein 
carbonylation in the gastrocnemius muscle of control (Co), Streptozotocin-induced diabetic 
mice (STZ) and N-acetylcystein-treated STZ mice (STZ+NAC). At the right side, 
densitometry analysis of protein carbonylation, which are expressed relative to Co mice. 
Values are means ± sem (n=3). * p<0.05 vs. Co, $ p<0.05 vs. STZ.  B: mRNA levels of 
oxidant and antioxidant enzymes, measured by real-time RT-PCR, in gastrocnemius muscle 
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of Co, STZ and STZ+NAC mice. Values are normalized to the levels of HPRT mRNA and 
expressed as relative amount compared to untreated STZ mice. Data are expressed as means ± 
sem (n=6-10). * p<0.05, ** p<0.01. 
 
Figure 5: Oxypurinol treatment specifically inhibited xanthine oxidase activity in 
skeletal muscle of STZ mice. Control or STZ-induced diabetic mice were studied 12 days 
after the first injection of sodium citrate buffer or STZ, and oxypurinol was added to drinking 
water of STZ mice during the last 5 days of the protocol. Xanthine oxidase (XO), NADPH 
oxidase and NO synthase activities were measured in muscle lysates of Co, STZ and 
oxypurinol-treated STZ mice. Values (n=5) are expressed as fold vs. enzyme activity in Co 
mice. 
 
Figure 6: Oxypurinol treatment restored alterations of mitochondria structure in 
skeletal muscle of STZ mice. Control or STZ-induced diabetic mice were studied 12 days 
after the first injection of sodium citrate buffer or STZ, and oxypurinol was added to drinking 
water of STZ mice during the last 5 days of the protocol. Transmission electron microscopy 
images (original magnification, x15,000 or x 40,000) of a representative muscle fiber (1st 
column), and of a zoom on subsarcolemmal (2nd column) and intermyofibrillar (3rd column) 
mitochondria from the gastrocnemius muscle of control (Co), streptozotocine-induced 
diabetic mice (STZ) and  oxypurinol-treated STZ mice. Arrows point mitochondria swelling, 
increased disarrayed cristae and reduced electron density of the matrix. 
 
Figure 7: Oxypurinol treatment improved mitochondria function in skeletal muscle of 
STZ mice. Control or STZ-induced diabetic mice were studied 12 days after the first injection 
of sodium citrate buffer or STZ, and oxypurinol was added to drinking water of STZ mice 
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during the last 5 days of the protocol. ATP synthesis was measured on isolated mitochondria 
from gastrocnemius muscle of control (Co), streptozotocine-induced diabetic mice (STZ) and 
oxypurinol-treated STZ mice. Values are the means ± sem (n=5). * p<0.05 vs. Co, # p< 0.05 
vs. STZ. 
 
Figure 8: Oxypurinol treatment restored alterations of mitochondria structure in 
skeletal muscle of high fat and high sucrose diet (HFHSD)-induced diabetic mice. Mice 
were fed either with standard diet (SD) or with high fat and high sucrose diet  (HFHSD) 
during 16 weeks. Oxypurinol was added in the drinking water of HFHSD mice during the 16 
week of feeding. Transmission electron microscopy images (original magnification, x15,000 
or x 40,000) of a representative muscle fiber (1st column), and of a zoom on subsarcolemmal 
(2nd column) and intermyofibrillar (3rd column) mitochondria from the gastrocnemius muscle 
of SD, HFHSD and oxypurinol-tretaed HFHSD mice. Arrows point mitochondria swelling, 
increased disarrayed cristae and reduced electron density of the matrix. 
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Tables 
 
Table1: Characteristics of mice (experiment 1). Body weight, glycaemia, insulinemia and 
plasma H2O2 concentrations of control (Co), untreated streptozotocin-treated mice (STZ), and 
insulin (STZ+INS)-treated STZ mice.   
 
 Co STZ STZ+INS 
Body weight (g) 24.5 ± 0.3 19.6 ± 0.6# 22 ± 0.4** 
Glucose (mg/dl) 184 ± 4 598 ± 21# 484 ± 22** 
Insulin (ng/ml) 1.2 ± 0.2 0.27 ± 0.03# 13.8 ±3.2** 
H2O2 (µM) 34.8 ± 5 77 ± 5# 47.6 ± 4.7* 
 
Data represent the means ± sem of 16 mice per group. 
# p<0.001 vs Co mice 
* p<0.05, ** p<0.01 vs STZ mice 
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Table 2: Characteristics of mice (experiment 2). Body weight, glycaemia, insulinemia and 
plasma H2O2 concentrations of control (Co), untreated streptozotocin-treated mice (STZ), and 
N-acetylcysteine (STZ+NAC)- or oxypurinol (STZ+OXY)-treated STZ mice.   
 
 Co STZ STZ+NAC STZ+OXY 
Body weight (g) 24.7 ± 0.5 21.2 ± 0.4# 20.6 ± 0.4 20.9 ± 0.6 
Glucose (mg/dl) 157 ± 3 654 ± 5# 557 ± 33* 636 ± 24 
Insulin (ng/ml) 2.2 ± 0.4 0.22 ± 0.01# 0.18 ± 0.01 0.25 ± 0.03 
H2O2 (µM) 30.5 ± 2 67.7 ± 4# 56.1 ± 5.3 43.3 ± 3.6* 
 
Data represent the means ± sem of 10 mice per group. 
# p<0.001 vs Co mice 
* p<0.01 vs STZ mice 
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Table 3: Characteristics of mice (experiment 3). Body weight, glycaemia, insulinemia, area 
under curve for both IPGTT and IPITT and plasma H2O2 concentrations of standard diet fed 
mice (SD), untreated high fat and high sucrose fed mice (HFHSD), and oxypurinol-treated 
HFHSD mice (HFHSD+OXY).   
 
 SD HFHSD HFHSD+OXY 
Body weight (g) 27 ± 0.5 44.7 ± 1.1* 45.5 ± 1.4 
Glucose (mg/dl) 135 ± 5 192.3 ± 5.7* 184.2 ±9.7 
Insulin (ng/ml) 0.5 ± 0.05 3.7 ± 0.7* 4.2 ± 0.7 
AUC for IPGTT (a.u.) 1 ± 0.2 1.55 ± 0.28 * 1.45 ± 0.35  
AUC for IPITT (a.u.) 1 ± 0.3 3.42 ± 0.25 * 3.1 ± 0.15  
H2O2 (µM) 28 ± 4 43.5 ± 4* 30.1 ± 6# 
 
Data represent the means ± sem of 10 mice per group. 
* p<0.01 vs SD mice, # p<0.05 vs. untreated HFHSD mice 
AUC: area under curve, IPGTT: intraperitoneal glucose tolerance test, ITT: intraperitoneal 
insulin tolerance test. 
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